Usman Mohammad

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, The Lancet.

Acute hyperventilation increases the central venous-to-arterial PCO2 difference in stable septic shock patients

D. Thévenin, J. Mallat, M. Lemyze, 2017, Annals of Intensive Care.

Delayed but successful response to noninvasive ventilation in COPD patients with acute hypercapnic respiratory failure

D. Thévenin, J. Mallat, M. Lemyze, 2017, International Journal of COPD.

Central Venous-to-Arterial Pco2 Difference and Central Venous Oxygen Saturation in the Detection of Extubation Failure in Critically Ill Patients*

D. Thévenin, J. Mallat, M. Fischer, 2020, Critical care medicine.

Overview of the current use of levosimendan in France: a prospective observational cohort study

A. Mebazaa, D. Tonon, E. Puymirat, 2023, Annals of Intensive Care.

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Jan van den Berg, Louis B. Bartels, H. Heidbuchel, 2022, Lancet.

Overview of the current use of levosimendan in France: a prospective observational cohort study

A. Mebazaa, D. Tonon, E. Puymirat, 2023, Annals of Intensive Care.